inobrodib + pomalidomide + dexamethasone

This is an **oral combination therapy** under clinical investigation for **relapsed/refractory multiple myeloma** consisting of inobrodib, pomalidomide, and dexamethasone. - **Inobrodib** is a first-in-class small molecule inhibitor that targets **p300 and CBP**, both of which are transcriptional coactivators regulating genes crucial for cancer cell survival and proliferation. Inhibiting these proteins disrupts regulatory control of oncogenes such as IRF4 and MYC, critical in multiple myeloma pathogenesis[2][4][7]. - **Pomalidomide** is an immunomodulatory drug (IMiD) that induces tumor cell death mainly through cereblon modulation, leading to the degradation of Ikaros proteins, activation of T and NK cells, and inhibition of angiogenesis[3][6]. - **Dexamethasone** is a synthetic glucocorticoid used as an anti-inflammatory and immunosuppressant, frequently employed to supplement anti-myeloma regimens. The combination is being tested in advanced, heavily pre-treated myeloma patients refractory to other classes, offering a convenient all-oral regimen. Early-phase results (mainly phase I/IIa) suggest promising efficacy, including in patients previously refractory to pomalidomide, with tolerable hematologic toxicities and no unexpected safety signals[1][2][4][7].

Other names

InoPd (sometimes used for this combination in academic presentations)